Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,106.55 -3.39 (-0.31%)
Streaming Delayed Price Updated: 3:57 PM EST, Nov 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Eli Lilly’s Weight-Loss Drug Mounjaro Becomes India’s Top-Selling Medicine By Value: Report ↗
The drug has surpassed GlaxoSmithKline’s antibiotic Augmentin, according to a Reuters report on Friday, citing data from research firm Pharmarack. 
Via Stocktwits
Topics Government
News headline image
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗
The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned. 
Via Investor's Business Daily
Topics Government
News headline image
Eli Lilly Stock Defies Trump’s GLP-1 Pricing Pressure With 6-Day Rally As Wall Street Cheers FDA Boost And New Weight-Loss Drug Data ↗
Bank of America Securities called Lilly’s GLP-1 pricing deal “probably a good tradeoff overall,” keeping a ‘Buy’ rating and $950 target. 
Via Stocktwits
Topics Government World Trade
News headline image
Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced ↗
Citi calls Trump’s GLP-1 pricing deal “less bad than feared,” while Needham warns it could erode Hims’ cost advantage. 
Via Stocktwits
Topics Government World Trade
Trump Announces Deals With Eli Lilly, Novo Nordisk To Lower Obesity Drug Prices ↗
Via Stocktwits
Topics Government
Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years? ↗
Via Stocktwits
News headline image
Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts ↗
Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for Zepbound and Wegovy by 2026. 
Via Benzinga
Topics Government
News headline image
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx ↗
The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026. 
Via Benzinga
Topics Government
News headline image
Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know. ↗
Is the fourth time the charm for this Danish pharmaceutical giant? 
Via The Motley Fool
Topics Earnings
News headline image
Trump Slashes Weight-Loss Drug Prices By Up To 74% In Deal With Lilly, Novo ↗
The Trump administration announced deals Thursday with Eli Lilly and Novo Nordisk to slash the prices of their obesity drugs. 
Via Investor's Business Daily
Topics Government
News headline image
Navigating the Volatility: Q3 2025 Earnings Season Delivers Both Cheers and Concerns
The third-quarter 2025 earnings season, largely drawing to a close in early November, has proven to be a dynamic and often surprising period for investors. While a significant majority of S&P 500... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025.... 
Via MarketMinute
Topics Intellectual Property
News headline image
My 6 Top-Ranked Stocks to Buy Right Now in November ↗
Whether you're looking for AI stocks or dividend stocks, there is something for everyone in this list. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Trump Administration's Weight-Loss Drug Deal Is Sending This Novo Nordisk Rival Surging: Momentum Score Spikes ↗
A leading pharmaceutical stock that goes head-to-head against Novo Nordisk A/S is surging amid a potential deal with the Trump administration. 
Via Benzinga
Topics Government
News headline image
Dow Jumps Over 200 Points: Investor Sentiment Improves, Fear & Greed Index Remains In 'Extreme Fear' Zone ↗
The CNN Fear & Greed Index eased, but remained in Extreme Fear zone on Wed. Stocks rose on solid earnings & speculation of Fed rate cut. 
Via Benzinga
Topics Economy Stocks
News headline image
1 Mid-Cap Stock for Long-Term Investors and 2 We Question
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
News headline image
ANI Pharmaceuticals (ANIP) To Report Earnings Tomorrow: Here Is What To Expect
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting results this Friday before the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Reasons I'm Keeping My Eye on Eli Lilly Stock Right Now ↗
Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy. 
Via The Motley Fool
Microsoft Gets $135 Billion OpenAI Stake ↗
Via The Motley Fool
News headline image
The Shifting Sands of Valuation: Understanding Market Cap Movers in a Dynamic Market
In the intricate tapestry of global financial markets, few metrics hold as much sway and immediate relevance as market capitalization. Representing the total dollar value of a company's outstanding... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Earnings
News headline image
The Resilient Market: Investor Optimism and the Enduring Power of "Dip-Buying" in November 2025
As November 2025 unfolds, the financial markets are characterized by a palpable sense of cautious optimism, a sentiment largely underpinned by the continued prevalence and success of "dip-buying"... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Tech Titans and Pharma Powerhouses Drive Market Volatility: AMD, Palantir, Micron, and Eli Lilly in Focus
As of November 5, 2025, the financial markets experienced a day of notable activity, with several key players across the technology and pharmaceutical sectors capturing investor attention. Advanced... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Obesity Drugmakers Face Shifting Tides: Novo Nordisk Plunges While Eli Lilly Soars
The burgeoning market for obesity and diabetes treatments, particularly GLP-1 receptor agonists, is witnessing a dramatic divergence in fortunes among its leading players. As of November 5, 2025, Novo... 
Via MarketMinute
Topics Economy
News headline image
Market Recovers from Tariff Turmoil: Dow, S&P 500, and Nasdaq Stage Resilient Rebound Amid Shifting Economic Winds
The U.S. financial markets have demonstrated remarkable resilience in 2025, staging a significant rebound after experiencing a sharp selloff earlier in the year. The Dow Jones Industrial Average, S&P... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday? ↗
Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing... 
Via Benzinga
Topics Economy
News headline image
AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns
Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
News headline image
Market Movers: Eli Lilly, Cadre, BP, Kellanova, and Teva Soar to 52-Week Highs Amidst Shifting Economic Tides
In a period marked by cautious optimism and strategic pivots, several prominent companies across diverse sectors have recently defied broader economic uncertainties to achieve significant 52-week... 
Via MarketMinute
Topics Economy Intellectual Property Supply Chain
News headline image
Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain ↗
Stanley Druckenmiller's firm bought Viking Therapeutics stock (VKTX) during Q2 at $25.33. Now up 36%, VKTX shows a Golden Cross. 
Via Benzinga
News headline image
Jim Cramer Says 'Take A Pass' On This Tech Stock, Won't Go Near Oils ↗
Zoom Communications is a good company, Cramer says. Still, he advises, "take a pass." Plus: Viking Therapeutics, Profrac and Altria. 
Via Benzinga
News headline image
Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy ↗
The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.